CoChat

Co-delivery of doxorubicin and shRNA of Beclin1 by folate receptor targeted pullulan-based multifunctional nanomicelles for combinational cancer therapy

Open access

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

New folate receptor targeted nano-micelles enhanced the anticancer effect of doxorubicin by shBeclin1 with the blockade of the autophagy process.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1039/c8ra01679h

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Scheme 1 Synthesis scheme of FPDP and illustration of tumor targeting strategy of FPDP nano-micelles for the simultaneous co-delivery of drug and shRNA into cancer cells.
Scheme 1 Synthesis scheme of FPDP and illustration of tumor targeting strategy of FPDP nano-micelles for the simultaneous co-delivery of drug and shRNA into cancer cells.CC BY-NC · PubMed Central
Fig. 1 Characterization of FPDP micelles. 1H NMR spectra of (A) PDP and (B) FPDP; (C) stability of FPDP micelles in 10% serum; (D) transmission electron microscopy images of FPDP (E) hemolysis test results different concentrations of FPDP after incubation with red blood cells suspension of sheep blood for 3 h; (F) viability of different cells assayed by MTT after the cells were treated with FPDP at different concentrations for 48 h.
Fig. 1 Characterization of FPDP micelles. 1H NMR spectra of (A) PDP and (B) FPDP; (C) stability of FPDP micelles in 10% serum; (D) transmission electron microscopy images of FPDP (E) hemolysis test results different concentrations of FPDP after incubation with red blood cells suspension of sheep blood for 3 h; (F) viability of different cells assayed by MTT after the cells were treated with FPDP at different concentrations for 48 h.CC BY-NC · PubMed Central
Fig. 2 (A) DOX release profiles of FPDP/DOX micelles at different pH; (B) the cellular uptake of free DOX and FPDP/DOX micelles by HeLa and HepG2 cells assayed by a flow cytometer and (C) by CLSM imaging (blue represents nuclei and red represents DOX); (D) cytotoxicity of free DOX and FPDP/DOX micelles at different DOX concentrations after incubation of 24 h; (E) the cellular uptake of free DOX and FPDP/DOX micelles for 8 h against HeLa and HepG2 cells after treatment with or without folic acid (5 mg mL−1); (F) the cellular uptake of FPDP/DOX by HeLa cells pre-incubated in culture medium containing different concentrations of FA.
Fig. 2 (A) DOX release profiles of FPDP/DOX micelles at different pH; (B) the cellular uptake of free DOX and FPDP/DOX micelles by HeLa and HepG2 cells assayed by a flow cytometer and (C) by CLSM imaging (blue represents nuclei and red represents DOX); (D) cytotoxicity of free DOX and FPDP/DOX micelles at different DOX concentrations after incubation of 24 h; (E) the cellular uptake of free DOX and FPDP/DOX micelles for 8 h against HeLa and HepG2 cells after treatment with or without folic acid (5 mg mL−1); (F) the cellular uptake of FPDP/DOX by HeLa cells pre-incubated in culture medium containing different concentrations of FA.CC BY-NC · PubMed Central
Fig. 3 ShRNA-binding of FPDP or FPDP/DOX micelles and transfection ability of FPDP/shRNA micelles in vitro. (A) Agarose gel electrophoresis retardation assay of shRNA by FPDP and (B) FPDP/DOX; (C) western blotting analysis for Beclin1 protein expression of HeLa cells after different treatment. (D) The intensity of Beclin1 expression quantified using Gel-Pro analyzer software. In experiments, shSCR and shBeclin1 concentration was at 1.87 μg mL−1, N/P = 10.
Fig. 3 ShRNA-binding of FPDP or FPDP/DOX micelles and transfection ability of FPDP/shRNA micelles in vitro. (A) Agarose gel electrophoresis retardation assay of shRNA by FPDP and (B) FPDP/DOX; (C) western blotting analysis for Beclin1 protein expression of HeLa cells after different treatment. (D) The intensity of Beclin1 expression quantified using Gel-Pro analyzer software. In experiments, shSCR and shBeclin1 concentration was at 1.87 μg mL−1, N/P = 10.CC BY-NC · PubMed Central
Fig. 4 In vitro antitumor effect of DOX and shBeclin1 co-delivery on HeLa cells incubated with different treatment by apoptosis analysis and MTT. (A) Apoptosis analysis by FCM; (B) cell viability assayed by MTT. In experiments, DOX concentration was set at 1.5 μg mL−1; shSCR and shBeclin1 concentration was at 1.87 μg mL−1, N/P = 10.
Fig. 4 In vitro antitumor effect of DOX and shBeclin1 co-delivery on HeLa cells incubated with different treatment by apoptosis analysis and MTT. (A) Apoptosis analysis by FCM; (B) cell viability assayed by MTT. In experiments, DOX concentration was set at 1.5 μg mL−1; shSCR and shBeclin1 concentration was at 1.87 μg mL−1, N/P = 10.CC BY-NC · PubMed Central
Fig. 5 In vivo antitumor activity of different treatment groups on HeLa tumor-bearing nude mice. (A) Tumor tissue volume images; (B) the tumor growth curve; (C) immunohistochemistry of Beclin1 performed in tumor sections; (D) body weight change of mice.
Fig. 5 In vivo antitumor activity of different treatment groups on HeLa tumor-bearing nude mice. (A) Tumor tissue volume images; (B) the tumor growth curve; (C) immunohistochemistry of Beclin1 performed in tumor sections; (D) body weight change of mice.CC BY-NC · PubMed Central
Fig. 6 Histologic assessments of major organs with HE staining in mice.
Fig. 6 Histologic assessments of major organs with HE staining in mice.CC BY-NC · PubMed Central
Fig. 7 In vivo bioimaging of DOX delivered by FPDP nano-complexes or its reference formulations injected into tumor-bearing nude mice monitored by an NIR fluorescence imaging system.
Fig. 7 In vivo bioimaging of DOX delivered by FPDP nano-complexes or its reference formulations injected into tumor-bearing nude mice monitored by an NIR fluorescence imaging system.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

Metadata

Authors
Chen, L., Qian, M., Zhang, L., Xia, J., Bao, Y., Wang, J., Guo, L., & Li, Y.
Affiliations
  • Dalian University of Technology (CN)
  • Dalian Medical University (CN)
Corresponding author
  • Wang, Jingyun
  • Li, Yachen
Venue
RSC Advances
Published
2018
Volume
8
Issue
32
Pages
17710-17722
ISSN
2046-2069 (ISSN-L)
OpenAlex
W2803886033
Cited by
38
References
50
Citations by year
2026: 1 · 2025: 5 · 2024: 6 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 4 · 2019: 5 · 2018: 3
FWCI
1.46
Type
journal article
Language
en
Open access
Locations
  • RSC Advances (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
National Natural Science Foundation of China (21376039, U1608222)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
doxorubicin, Beclin-1, shRNA, folate receptor targeting, pullulan, nanomicelles, RNA interference, combination cancer therapy, anticancer drug delivery, antitumor efficacy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.